接受抗凝治疗的心房颤动患者的死亡原因
该系统综述与荟萃分析纳入4项直接口服抗凝药与华法林对比的随机试验,共71,683例心房颤动患者(134,046患者年随访),随访期间9%患者死亡。心脏性死亡占全部死亡的46%,非出血性卒中/系统性栓塞和出血相关死亡分别占5.7%和5.6%。直接口服抗凝药较华法林降低全因死亡率(年差异-0.42%,95%CI:-0.66至-0.18),主要由致死性出血减少驱动。
要点
- 心脏性死亡占全部死亡的46%,非出血性卒中/系统性栓塞和出血相关死亡各占5.7%和5.6%。
- 直接口服抗凝药较华法林降低全因死亡率(年差异-0.42%,95%CI:-0.66至-0.18)。
- 死亡患者更多有心力衰竭、永久性/持续性心房颤动和糖尿病史,且年龄更大、肌酐清除率更低。
核心结论
- 当代心房颤动试验中大多数死亡为心脏性死亡,卒中和出血仅占死亡的小部分。
- 除抗凝外还需其他干预措施以进一步降低心房颤动患者的死亡率。
研究设计与样本
- 系统检索直接口服抗凝药与华法林对比预防心房颤动患者卒中/系统性栓塞的随机试验。
- 纳入4项试验共71,683例患者,随访134,046患者年,采用随机效应模型进行荟萃分析。
- 主要结局为死亡率和独立判定的具体死亡原因。
主要发现
- 随访期间共6,206例患者(9%)死亡,校正死亡率为每年4.72%(95%CI:4.19至5.28)。
- 心脏性死亡占全部死亡的46%,非出血性卒中/系统性栓塞占5.7%,出血相关死亡占5.6%。
- 与存活患者相比,死亡患者更多有心力衰竭史(OR:1.75;95%CI:1.25至2.44)、永久性/持续性心房颤动(OR:1.38;95%CI:1.25至1.52)和糖尿病(OR:1.37;95%CI:1.11至1.68)。
- 死亡患者更多为男性(OR:1.24;95%CI:1.13至1.37)、年龄更大(平均差3.2岁;95%CI:1.6至4.8)、肌酐清除率更低(-9.9 ml/min;95%CI:-11.3至-8.4)。
- 直接口服抗凝药较华法林降低全因死亡率(年差异-0.42%;95%CI:-0.66至-0.18),主要由致死性出血减少驱动。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oral anticoagulation reduces the risk of mortality in atrial fibrillation (AF), but examination of the causes of death is essential to design new strategies to further reduce the high mortality rates observed in this population. OBJECTIVES: The authors sought to analyze and compare causes of death in patients receiving direct oral anticoagulants (DOAC) or warfarin for prevention of stroke and systemic embolism (SE) in AF. METHODS: The authors systematically searched for randomized trials of DOAC versus warfarin for prevention of stroke/SE in AF. The main outcome was mortality and independently adjudicated specific causes of death. The authors used the random effects model of meta-analysis to combine the studies. RESULTS: 71,683 patients from 4 trials were included (134,046 patient-years of follow-up). A total of 6,206 patients (9%) died during follow-up. Adjusted mortality rate was 4.72%/year (95% confidence interval [CI]: 4.19 to 5.28). Cardiac deaths accounted for 46% of all deaths, whereas nonhemorrhagic stroke/SE and hemorrhage-related deaths represented 5.7% and 5.6% of the total mortality, respectively. Compared with patients who were alive, those who died had more frequent history of heart failure (odds ratio [OR]: 1.75; 95% CI: 1.25 to 2.44), permanent/persistent AF (OR: 1.38; 95% CI: 1.25 to 1.52) and diabetes (OR: 1.37; 95% CI: 1.11 to 1.68); were more frequently male (OR: 1.24; 95% CI: 1.13 to 1.37) and older (mean difference 3.2 years; 95% CI: 1.6 to 4.8); and had a lower creatinine clearance (-9.9 ml/min; 95% CI: -11.3 to -8.4). There was a small, but significant, reduction in all-cause mortality with the DOAC versus warfarin (difference -0.42%/year; 95% CI: -0.66 to -0.18), mainly driven by a reduction in fatal bleedings. CONCLUSIONS: In contemporary AF trials, most deaths were cardiac-related, whereas stroke and bleeding represented only a small subset of deaths. Interventions beyond anticoagulation are needed to further reduce mortality in AF.
引用
- Gómez-Outes A, Lagunar-Ruíz J, Terleira-Fernández AI, et al. Causes of Death in Anticoagulated Patients With Atrial Fibrillation. J Am Coll Cardiol. 2016. PMID: 27931607. doi:10.1016/j.jacc.2016.09.944
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。